Financial Performance - The company achieved operating revenue of ¥287,684,655.66, representing a year-on-year increase of 6.37%[5] - Net profit attributable to shareholders reached ¥50,331,897.74, up 1.34% compared to the previous year[5] - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥47,388,468.47, reflecting a growth of 4.74%[5] - Total assets at the end of the reporting period amounted to ¥638,381,303.84, an increase of 13.67% from the beginning of the period[5] - Shareholders' equity attributable to the company was ¥514,435,560.78, up 6.25% from the beginning of the period[5] - Basic earnings per share remained stable at ¥0.64, with no change from the previous year[3] - The weighted average return on net assets (after deducting non-recurring items) was 9.63%, slightly up from 9.51% in the previous year[3] Capital Changes - The company's share capital increased by 40.00% to ¥78,708,700.00 due to the implementation of a stock dividend plan[6] Strategic Initiatives - The company is actively expanding market share and optimizing product sales structure to enhance competitiveness and profitability[6] Audit and Reporting - The financial data presented is preliminary and subject to audit, with final figures to be disclosed in the 2025 annual report[7]
峆一药业(920478) - 2025 Q4 - 年度业绩